Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Viatris Inc.NASDAQ: VTRS

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $248.3M rose 13.5% year over year, behind the +20.8% change in trailing-twelve-month research & development. Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Research & development amounted to 6.8% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.5% toward the trailing-twelve-month pace of +20.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$248.3M-0.1% QoQ
Last fiscal yearDec 2025
$965.9M+19.4% YoY
LTMJun 2026
$1.02B+20.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.5%——
1 year+19.4%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
965.9M USD
Year-over-year change
+19.4%
4-year CAGR
+9.1%

Research & Development vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +20.8% is the 2nd highest of 9, against a peer median of +0.3%.
  • Research & development amounts to 6.9% of revenue for VTRS, versus a peer median of 5.8%.
VTRS Competitors
Research & Development for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹22.73B INR-13.8%+9.3%6.9%
VTRSViatris Inc.LTM Jun 2026$1.02B USD+20.8%+13.4%6.9%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$995M USD-0.7%+6.5%5.7%
BHCBausch Health Companies Inc.LTM Jun 2026$634M USD+1.3%+5.9%5.8%
HLNHaleon plcLTM Jun 2025£459.5M GBP—+0.9%2.8%
ALKSAlkermes plcLTM Sep 2026$430.42M USD+49.7%+5.9%24.5%
OGNOrganon & Co.LTM Sep 2026$357M USD-11.9%-8.1%5.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$177.66M USD-15.0%-3.7%5.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$92.49M USD+20.2%+4.7%12.8%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$51.7M USD+15.8%+32.3%5.6%
Peer median (excluding VTRS) —+0.3%+5.9%5.8%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.